Metadata
Title PHD: Pertuzumab + Trastuzumab + Docetaxel — Metastatic HER2+ Breast Cancer
Version 0.1.1-snapshot-080926
Experimental true
Subject Type Malignant neoplasm of breast
Jurisdiction United States of America
Steward (Publisher) HL7 International / Clinical Interoperability Council
Steward Contact HL7 International / Clinical Interoperability Council
Description

PHD regimen every 21 days for HER2+ metastatic breast cancer. Standard of care per CLEOPATRA trial.
Type Order Set
PlanDefinition Action
Id pertuzumab-phd
Title Pertuzumab 840 mg IV (cycle 1), then 420 mg IV q21d
Timing Once per 21 days
PlanDefinition Action
Id trastuzumab-phd
Title Trastuzumab 8 mg/kg IV (cycle 1), then 6 mg/kg IV q21d
Timing Once per 21 days
PlanDefinition Action
Id docetaxel-phd
Title Docetaxel 75 mg/m² IV — Day 1 of each 21-day cycle
Timing Once per 21 days
Generated using version 0.5.4 of the sample-content-ig Liquid templates
<type> <coding> <system value="http://terminology.hl7.org/CodeSystem/plan-definition-type"/> <code value="order-set"/> <display value="Order Set"/> </coding> </type> <status value="active"/> <experimental value="true"/> <subjectCodeableConcept> <coding> <system value="http://snomed.info/sct"/> <code value="254837009"/> <display value="Malignant neoplasm of breast"/> </coding> </subjectCodeableConcept> <date value="2026-09-08T18:17:28-04:00"/> <publisher value="HL7 International / Clinical Interoperability Council"/> <contact> <name value="HL7 International / Clinical Interoperability Council"/> <telecom> <system value="url"/> <value value="http://www.hl7.org/Special/committees/cic"/> </telecom> <telecom> <system value="email"/> <value value="ciclist@lists.HL7.org"/> </telecom> </contact> <description value="PHD regimen every 21 days for HER2+ metastatic breast cancer. Standard of care per CLEOPATRA trial."/> <jurisdiction> <coding> <system value="urn:iso:std:iso:3166"/> <code value="US"/> <display value="United States of America"/> </coding> </jurisdiction> <action id="pertuzumab-phd"> <title value="Pertuzumab 840 mg IV (cycle 1), then 420 mg IV q21d"/> <timingTiming> <repeat> <period value="21"/> <periodUnit value="d"/> </repeat> </timingTiming> </action> <action id="trastuzumab-phd"> <title value="Trastuzumab 8 mg/kg IV (cycle 1), then 6 mg/kg IV q21d"/> <timingTiming> <repeat> <period value="21"/> <periodUnit value="d"/> </repeat> </timingTiming> </action> <action id="docetaxel-phd"> <title value="Docetaxel 75 mg/m² IV — Day 1 of each 21-day cycle"/> <timingTiming> <repeat> <period value="21"/> <periodUnit value="d"/> </repeat> </timingTiming> </action> </PlanDefinition>